Effector function of CLA+ T lymphocytes on autologous keratinocytes in psoriasis;Función efectora de linfocitos T CLA+ sobre queratinocitos autólogos en psoriasis

Actas Dermo-Sifiliograficas

Volumn 99, Issue 9, 2008, Pages 701-707

  Ferran, M ^a   Gimenez Arnau A M ^a   Bellosillo, B ^a   Pujol, R M ^a   Santamaria Babi L F ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Cutaneous lymphocyte antigen; Inducible nitric oxide synthase; Keratinocyte; Psoriasis

Indexed keywords

CD28 ANTIGEN; CD3 ANTIBODY; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA DR ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; CTAGE1 PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR ANTIGEN;

ARTICLE; CELL FUNCTION; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; KERATINOCYTE; PSORIASIS; T LYMPHOCYTE ACTIVATION; IMMUNOLOGY; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; HUMANS; KERATINOCYTES; MEMBRANE GLYCOPROTEINS; PSORIASIS; T-LYMPHOCYTES;

EID: 63249128205     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/s1578-2190(08)70346-9     Document Type: Article

References (39)

1. Santamaría-Babi LF. CLA (+) T cells in cutaneous diseases. Eur J Dermatol. 2004;14:13-8.
2. Chen GY, Osada H, Santamaría-Babi LF, Kannagi R. Interaction of GATA-3/T-bet transcription factors regulates expression of sialyl Lewis X homing receptors on Thl/Th2 lymphocytes. Proc Natl Acad Sci USA. 2006;103:16894-9.
3. Santamaría-Babi LF. Skin-homing T cells in cutaneous allergic inflammation. Chem Immunol Allergy. 2006;91:87-97.
4. Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol. 2005;5: 699-711.
5. Nickoloff BJ, Nestle FO. Recent insights into the immuno-pathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113:1664-75.
6. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866-73.
7. Pont-Giralt M, Giménez-Arnau AM, Pujol RM, Santamaria-Babi LF. Circulating CLA(+) T cells from acute and chronic psoriasis patients manifest a different activation state and correlation with disease severity and extension. J Invest Dermatol. 2006;126:227-8.
8. Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Surer M, Nesde FO. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med. 2004;199:731-6.
9. Picker LJ, Michie SA, Rott LS, Butcher EC. A unique phe-notype of skin-associated lymphocytes in humans. Preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol. 1990;136: 1053-68.
10. Lew W, Bowcock AM, Krueger JG. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and Type 1 inflammatory gene expression. Trends Immunol. 2004;25: 295-305.
11. Santamaria Babi LF, Moser R, Pérez Soler MT, Picker LJ, Blaser K, Hauser C. Migration of skin-homing T cells across cytokine-activated human endothelial cell layers involves interaction of the cutaneous lymphocyte-associated antigen (CLA), the very late antigen-4 (VLA-4), and the lymphocyte function-associated antigen-1 (LFA-1) J Immunol. 1995;154:1543-50.
12. Parent D, Bernard BA, Desbas C, Heenen M, Darmon MY. Spreading of psoriatic plaques: alteration of epidermal differentiation precedes capillary leakiness and anomalies in vascular morphology. J Invest Dermatol. 1990;95:333-40.
13. Ragaz A, Ackerman AB. Evolution, maturation, and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings. Am J Dermatopathol. 1979;1:199-214.
14. Davison SC, Ballsdon A, Allen MH, Barker JN. Early migration of cutaneous lymphocyte-associated antigen (CLA) positive T cells into evolving psoriatic plaques. Exp Dermatol. 2001;10:280-5.
15. +) T cells appear early in the marginal zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol. 2004;150:852-9.
16. + T cells migrate through superficial vascular plexus but not through deep vascular plexus endothelium. J Invest Dermatol. 1997;108:343-8.
17. Biedermann T, Schwarzler C, Lametschwandtner G, Thoma G, Carballido-Perrig N, Kund J, et al. Targeting CLA/E-selectin interactions prevents CCR4-mediated recruitment of human Th2 memory cells to human skin in vivo. Eur J Immunol. 2002;32:3171-80.
18. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest. 1995;95:317-27.
19. Prinz JC, Gross B, Vollmer S, Trommler P, Strobel I, Meurer M, et al. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur J Immunol. 1994;24:593-8.
20. Santamaria Babi LF, Picker LJ, Pérez Soler MT, Drzimalla K, Flohr P, Blaser K, et al. Circulating allergen-reactive T cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen. J Exp Med. 1995; 181:1935-40.
21. Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E, et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol. 2000;164:6621-32.
22. Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity. 2002;16:1-4.
23. Cook PW, Piepkorn M, Clegg CH, Plowman GD, DeMay JM, Brown JR, et al. Transgenic expression of the human amphiregulin gene induces a psoriasis -like phenotype. J Clin Invest. 1997;100:2286-94.
24. Singer NG, Mitra R, Lialios F, Richardson BC, Marks RM, Pesando JM, et al. CD6 dependent interactions of T cells and keratinocytes: functional evidence for a second CD6 ligand on gamma-interferon activated keratinocytes. Immunol Lett. 1997;58:9-14.
25. Shimizu Y, Sakai M, Umemura Y, Ueda H. Immunohisto-chemical localization of nitric oxide synthase in normal human skin: expression of endothelial-type and inducible-type nitric oxide synthase in keratinocytes. J Dermatol 1997;24:80-7.
26. Sirsjo A, Karlsson M, Gidlof A, Rollman O, Torma H. Increased expression of inducible nitric oxide synthase in psoriatic skin and cytokine-stimulated cultured keratinocytes. Br J Dermatol. 1996;134:643-8.
27. Bruch-Gerharz D, Schnorr O, Suschek C, Beck KF, Pfeils-chifter J, Ruzicka T, et al. Arginase 1 overexpression in psoriasis: limitation of inducible nitric oxide synthase activity as a molecular mechanism for keratinocyte hyperproliferation. Am J Pathol. 2003;162:203-11.
28. Arany I, Brysk MM, Brysk H, Tyring SK. Regulation of inducible nitric oxide synthase mRNA levels by differentiation and cytokines in human keratinocytes. Biochem Biophys Res Commun. 1996;220:618-22.
29. Ormerod AD, Weller R, Copeland P, Benjamin N, Ralston SH, Grabowksi P, et al. Detection of nitric oxide and nitric oxide synthases in psoriasis. Arch Dermatol Res. 1998;290: 3-8.
30. Bruch-Gerharz D, Fehsel K, Suschek C, Michel G, Ruzicka T, Kolb-Bachofen V. A proinflammatory activity of interleu-kin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytes. J Exp Med. 1996;184:2007-12.
31. Suschek CV, Schnorr O, Kolb-Bachofen V. The role of iNOS in chronic inflammatory processes in vivo: is it damage-promoting, protective, or active at all? Curr Mol Med. 2004;4:763-75.
32. Namazi MR. Explaining decreased nitric oxide production in psoriatic lesions: arginase 1 overexpression versus calcitonin gene-related peptide. Am J Pathol. 2003;163:2642.
33. Tekin NS, liter N, Sancak B, Ozden MG, Gurer MA. Nitric oxide levels in patients with psoriasis treated with methotrexate. Mediators Inflamm. 2006;2006:16043
34. Kotenko SV. The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev. 2002;13:223-40.
35. Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol. 2002;169:4288-97.
36. Romer J, Hasselager E, Norby PL, Steiniche T, Thorn Clausen J, Kragballe K. Epidermal overexpression of interleu-kin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J Invest Dermatol. 2003;121:1306-11.
37. Kunz S, Wolk K, Witte E, Witte K, Doecke WD, Volk HD, et al. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol. 2006;15:991-1004.
38. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med. 2003;9:40-6.
39. Otkjaer K, Kragballe K, Funding AT, Clausen JT, Noerby PL, Steiniche T, et al. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. Br J Dermatol. 2005;153:911-8.